Conversion Labs, Inc. (CVLB) News
Filter CVLB News Items
CVLB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CVLB News Highlights
- For CVLB, its 30 day story count is now at 3.
- Over the past 6 days, the trend for CVLB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CVLB are MD, ARR and CMA.
Latest CVLB News From Around the Web
Below are the latest news stories about Conversion Labs Inc that investors may wish to consider to help them evaluate CVLB as an investment opportunity.
15 retailers at risk of default: reportS&P Global Market Intelligence lists 15 retailers as most vulnerable to a default in a new report. |
Conversion Labs to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, has been invited to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held on February 17-19, 2021. Conversion Labs CEO Justin Schreiber is scheduled to present in a fireside chat on Thursday, February 18 at 1:00 p.m. Eastern time. He will be joined by the company’s chief business officer, Corey Deutsch, for the presentation and virtual one-on-one meetings with institutional analysts and investors throughout the conference. The presentation will be webcast live and available for replay here and via the investor relations section of the company’s website at ConversionLabs.com. Management will discuss the comp... |
Conversion Labs to become Life MD with launch of new concierge telehealth servicesDirect-to-patient telehealth company Conversion Labs ([[CVLB]] +7.2%) said that it will change its name to Life MD later this month, followed by the official launch of its subscription-based primary care and concierge services offering.Upon the name change, the company expects its stock to begin trading under the symbol "LFMD".Life MD will offer... |
Conversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 MillionNEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth quarter and full year ended December 31, 2020. Revenue for the fourth quarter is expected to total $13.6 million, up 265% from $3.7 million in the fourth quarter of 2019. Revenue for the full year is expected to total $38.0 million, up 205% from $12.5 million in 2019. “Our strong performance in 2020 demonstrated our ability to provide accessible healthcare to an increasing number of patients across the country,” stated Conversion Labs CEO, Justin Schreiber. “We ended the year exceptionally strong, with December revenues hitting a monthly record of $5.1 million, up 321% over December of last year. In fac... |
Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical OfficerNEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist, Dr. Anthony Puopolo, to the new position of chief medical officer. Dr. Puopolo will be responsible for overseeing the company’s rapidly expanding network of state licensed physicians and ensuring that the company is delivering the highest quality of care. He will also work closely with Conversion Labs’ product and marketing teams to optimize the company’s telemedicine offerings and support expansion into new verticals.Dr. Puopolo brings to Conversion Labs more than 20 years of executive and professional healthcare experience, including serving in senior leadership positions at several m... |
Conversion Labs to Present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has been invited to present at H.C. Wainwright’s BioConnect Conference being held virtually on January 11-14, 2021. The company’s presentation will be available on-demand via the H.C. Wainwright conference portal here and in the investor relations section at ConversionLabs.com beginning at 6:00 a.m. Eastern time on Monday, January 11.Conversion Labs’ head of corporate development, Corey Deutsch, will discuss how the company’s recent accomplishments have translated into strong demand for its direct-to-consumer telemedicine products. This has resulted in a record annualized revenue run-rate of $53.9 million, with annual recurring revenue (ARR) from subscriptions at... |
Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital OfficerNEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant Hussey, to the new position of chief digital officer. He will lead the company’s marketing and customer retention efforts, as well as help launch new or enhanced telemedicine products, improve unit economics, and maximize patient lifetime value. Hussey brings to Conversion Labs more than 20 years of executive experience at direct-to-consumer and eCommerce companies, translating business goals into successful marketing campaigns. He specializes in lead generation, funnel optimization and customer retention that maximizes customer lifetime value and lowers cost per acquisition.Hussey previou... |
Conversion Labs Annualized Revenue Run-Rate Hits $53.9 Million, up 332% vs. 2019, Driven by Subscriptions to an Expanding Suite of Telehealth BrandsNEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, reported its annualized revenue run-rate reached a record $53.9 million in November, up 332% versus $12.5 million for all of 2019. The run-rate is based on record revenues of $4.5 million for the month, which was up 233% versus November of last year. Annual recurring revenue (ARR) generated by subscriptions reached $23.0 million, up by $19.2 million or 517% versus November 2019 (see description of ARR, below). The growth in ARR was driven by the company’s increasingly popular brands, particularly Rex MD for men’s health.“November was so strong, it eclipsed our entire first quarter revenue by a significant margin,” stated Conversion Labs CEO, Justin S... |
Shareholders Are Raving About How The Conversion Labs (NASDAQ:CVLB) Share Price Increased 986%Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit... |
Conversion Labs Launches Veritas MD™ Telehealth Platform, Delivering Greater Access to Growing Portfolio of Industry-Leading, Direct-to-Consumer Pharmacy and Wellness BrandsNEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, has officially launched its new Veritas MD telehealth platform, opening the door to greater market expansion with a growing portfolio of industry leading, direct-to-consumer pharmacy and wellness brands. Building upon its existing telemedicine infrastructure initially formed early last year, Veritas MD has been designed to deliver greater access and convenience to the rapidly growing number of consumers seeking medical treatment, prescription medications, and over-the-counter personal health products from the comfort and security of their home or office.Veritas MD integrates patient electronic health records and health care provider workflows across ... |